Head-to-head evidence
BPI-16350 vs Dalpiciclib
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
HR+/HER2- Metastatic Breast Cancer
Shared mechanism: CDK4 and CDK6 · full HR+/HER2- Metastatic Breast Cancer pipeline
BPI-16350
Developed by Betta Pharmaceuticals Co.
NCT05433480 · Phase 3 · status unknown
This randomised, quadruple-blind, placebo-controlled trial in 274 women with HR-positive, HER2-negative advanced breast cancer reported median progression-free survival of 16.5 months with tibremciclib plus fulvestrant against 5.6 months with placebo plus fulvestrant, a hard clinical endpoint.
Dalpiciclib
Developed by Jiangsu Hengrui Pharmaceuticals
NCT06009627 · Phase 2/3 · completed
The trial randomized 119 participants to an active chemotherapy comparator and used investigator masking, but it was not double-blind. Its primary endpoint was objective tumor response rate, and no primary endpoint results or statistical comparison have been posted, so the outcome cannot be judged as met or missed.
Next expected readout: October 2026 · NCT04842617 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: BPI-16350's landscape · Dalpiciclib's landscape